Hala Borno, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6554
San Francisco CA 94158
Phone415-476-1528
PronounsShe/Her/Hers
ORCID ORCID Icon0000-0002-4357-975 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFDiversity, Equity, and Inclusion Champion Training
    UCSFFellowship Hematology/Oncology
    UCSFResidency Internal Medicine
    UNC Chapel HillDoctor of MedicineSchool of Medicine
    UNC Chapel HillBachelor of ScienceBiochemistry
    Collapse Awards and Honors
    NIA2017  - 2019T32-AG000212
    Clinical Innovation Center UCSF2017  - 2018Inside Out Accelerator
    UCSF RAP2018  - 2019Integrative Pilot Award
    Prostate Cancer Foundation2018  - 2021Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Dr. Hala Borno is faculty at UCSF and an Associate Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, and GU committee for NRG oncology. She serves as the Vice Chair of the Health Disparities Committee for Alliance for Clinical Trials in Oncology.

    Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

    She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

    Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Med. 2024 Nov; 13(22):e70433. Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, Belkora J. PMID: 39569542; PMCID: PMC11579662.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy. Gynecol Oncol. 2024 Nov; 190:84-89. Guerra RA, Kaplan C, Borno H, Boscardin J, Alvarez EA, Lazar A, Chapman J, Swanson M, Ueda S, Chen LM. PMID: 39163751.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Qualitative Study on Internet Use and Care Impact for Black Men With Prostate Cancer. Health Educ Behav. 2024 06; 51(3):359-366. Loeb S, Sanchez Nolasco T, Byrne N, Allen L, Langford AT, Ravenell JE, Gomez SL, Washington SL, Borno HT, Griffith DM, Criner N. PMID: 38366884.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer. J Urol. 2024 Mar; 211(3):376-383. Loeb S, Sanchez Nolasco T, Byrne N, Allen L, Langford AT, Ravenell J, Gomez SL, Washington SL, Borno HT, Griffith DM, Criner N. PMID: 38329047.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):103-103. Kwon KD, Trihy TL, Hearst HE, Darvish DN, Kaur KG, Nesheiwat NS, Borno BH, Bose BR, Chou CJ, de Kouchkovsky dI, Desai DA, Fitzgerald FK, Fong FL, Friedlander FT, Koshkin KV, Small SE, Aggarwal AR, Belkora BJ. .
      View in: Publisher Site   Mentions:
    6. Advancing Equity in Oncology: Innovative Approaches and Robust Frameworks to Address Cancer Health Disparities. International Journal of Cancer Care and Delivery. 2023 Oct 18; 3(1). LaPelusa LM, Khan KH, Deville DC, Washington WS, Borno BH. .
      View in: Publisher Site   Mentions:
    7. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. Elife. 2023 10 17; 12. Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP, COVID-19 and Cancer Consortium. PMID: 37846664; PMCID: PMC10637772.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    8. The Effect of Racial Concordance on Patient Trust in Online Videos About Prostate Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2023 07 03; 6(7):e2324395. Loeb S, Ravenell JE, Gomez SL, Borno HT, Siu K, Sanchez Nolasco T, Byrne N, Wilson G, Griffith DM, Crocker R, Sherman R, Washington SL, Langford AT. PMID: 37466938; PMCID: PMC10357333.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    9. Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):5032-5032. Carretero-González CA, Kwon KD, Shakhnazaryan SN, Hong HJ, Mohamad MO, Feng FM, de Kouchkovsky dI, Borno BH, Bose BR, Chou CJ, Desai DA, Fong FL, Friedlander FT, Koshkin KV, Feng FF, Aggarwal AR, Hope HT, Small SE. .
      View in: Publisher Site   Mentions:
    10. Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e17010-e17010. Maldonado ME, Hope HT, Aggarwal AR, Kwon KD, Zhang ZL, Gordon GK, Tong TB, Bailey BA, Kumar KV, de Kouchkovsky dI, Koshkin KV, Borno BH, Chou CJ, Bose BR, Fong FL, Desai DA, Friedlander FT, Small SE. .
      View in: Publisher Site   Mentions:
    11. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR Cancer. 2023 Jun 01; 9:e45432. Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. PMID: 37261885; PMCID: PMC10273032.
      View in: PubMed   Mentions:
    12. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. The costs and inequities of precision medicine for patients with prostate cancer: A call to action. Urol Oncol. 2023 09; 41(9):369-375. Ragavan MV, Borno HT. PMID: 37164775.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. In Regard to Lastname et al. International Journal of Radiation Oncology • Biology • Physics. 2023 May 1; 116(1):14-15. Friedlander FT, Borno BH. .
      View in: Publisher Site   Mentions:
    15. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 6  
    16. Nutrition Guidance for Patients on Androgen Deprivation Therapy. Eur Urol Focus. 2023 05; 9(3):427-430. Kenfield SA, Van Blarigan EL, Graff RE, Borno HT, Macaire G, Chan JM. PMID: 36935290.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. medRxiv. 2023 Mar 10. Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, de Lima Lopes G, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP. PMID: 37205429; PMCID: PMC10187350.
      View in: PubMed   Mentions:
    18. Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer. Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):112-112. Thorn TA, Gordon GK, Tong TB, Kwon KD, Dhawan DM, Borno BH, Aggarwal AR, Small SE, Blanco BA. .
      View in: Publisher Site   Mentions:
    19. Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):532-532. Reyes RK, Zhang ZL, Zhu ZX, Jindal JT, Deshmukh DP, de Kouchkovsky dI, Kumar KV, Maldonado ME, Kwon KD, Chan CE, Porten PS, Borno BH, Bose BR, Desai DA, Aggarwal AR, Small SE, Fong FL, Chou CJ, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    20. Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB). Journal of Clinical Oncology. 2023 Feb 20; 41(6_suppl):534-534. Jindal JT, Zhu ZX, Zhang ZL, Reyes RK, Deshmukh DP, de Kouchkovsky dI, Kumar KV, Maldonado ME, Shipp SC, Kwon KD, Borno BH, Bose BR, Desai DA, Aggarwal AR, Porten PS, Small SE, Fong FL, Chou CJ, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    21. Experiences of a Multiethnic Cohort of Patients Enrolled in a Financial Reimbursement Program for Cancer Clinical Trials. JCO Oncol Pract. 2023 05; 19(5):e801-e810. Medina SP, Zhang S, Nieves E, Dornsife DL, Johnson R, Spicer D, Borno HT. PMID: 36800640.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Declining Representation and Reporting of Racial and Ethnic Minority Patients in Prostate Cancer Clinical Trials Despite Persistent Health Disparities-Where Progress Confronts Limitations. JAMA Oncol. 2023 02 01; 9(2):175-177. Deville C, Borno HT. PMID: 36520457.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer. JCO Oncol Pract. 2023 05; 19(5):e773-e783. Kwon DH, Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M. PMID: 36649492.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    24. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. PMID: 36528473.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 Pandemic. JAMA Oncol. 2022 12 01; 8(12):1849-1851. Ragavan MV, Legaspi N, LaLanne A, Hong JC, Small EJ, Borno HT. PMID: 36301577; PMCID: PMC9614670.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    26. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Impact of a Comprehensive Financial Resource on Financial Toxicity in a National, Multiethnic Sample of Adult, Adolescent/Young Adult, and Pediatric Patients With Cancer. JCO Oncol Pract. 2023 02; 19(2):e286-e297. Ragavan MV, Mora RV, Winder K, Incudine A, Cunningham R, Stivers T, Borno HT. PMID: 36378994.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    28. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633. Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    29. Reliability of real-world data for diagnosis of metastatic prostate cancer. Journal of Clinical Oncology. 2022 Sep 30; 40(28_suppl):397-397. Phuong PC, Lin LA, Friesner FI, Ni NL, Aggarwal AR, Borno BH, Koshkin KV, Desai DA, Friedlander FT, Fong FL, Bose BR, Chou CJ, Rodvelt RT, Mohamad MO, Wong WA, Feng FF, Small SE, Hong HJ. .
      View in: Publisher Site   Mentions:
    30. 1379P A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep 1; 33:s1173. Aggarwal AR, Trihy TL, Romero RE, Sam SS, Rastogi RM, De Kouchkovsky DI, Small SE, Feng FF, Kwon KD, Friedlander FT, Borno BH, Bose BR, Chou CJ, Koshkin KV, Desai DA, Feng FS, Angelidakis AA, Johnson JM, Fong FL, Hope HT. .
      View in: Publisher Site   Mentions:
    31. 1751P Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma (mUC) patients (pts) treated with newer therapies. Annals of Oncology. 2022 Sep 1; 33:s1338-s1339. Deshmukh DP, De Kouchkovsky DI, Zhang ZL, Jindal JT, Reyes RK, Romero RE, Chan CE, Desai DA, Borno BH, Kwon KD, Wong WA, Bose BR, Aggarwal AR, Porten PS, Fong FL, Small SE, Chou CJ, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    32. 1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results. Annals of Oncology. 2022 Sep 1; 33:s1187. Jindal JT, Han HH, Deshmukh DP, De Kouchkovsky DI, Kwon KD, Borno BH, Koshkin KV, Desai DA, Bose BR, Chou CJ, Friedlander FT, Small SE, Angelidakis AA, Johnson JM, Feng FS, Patnaik PA, Fong FL, Alumkal AJ, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    33. Ethnic and Racial Inequities in Cancer Screening During the COVID-19 Pandemic: a multi-site observational study in the United States. International Journal of Cancer Care and Delivery. 2022 Aug 23. Idossa ID, Borno BH, Wang WK, Pletcher PM, Gresham GG, Canchola CA, Bell BD, Matheny MM, Schilling SL, Perkins PA, Zheng ZK, Ohno-Machado OL, Kim KJ, Soohoo SS, Meeker MD, Gomez GS. .
      View in: Publisher Site   Mentions:
    34. Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer. International Journal of Cancer Care and Delivery. 2022 Jul 18. Younger YN, Borno BH. .
      View in: Publisher Site   Mentions:
    35. Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature Review. Front Oncol. 2022; 12:910115. Idossa D, Friedlander T, Paller CJ, Ryan CJ, Borno HT. PMID: 35875156; PMCID: PMC9301521.
      View in: PubMed   Mentions: 3  
    36. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. Urol Oncol. 2022 08; 40(8):379.e17-379.e24. Kwon DH, Kwon DH, Paciorek A, Zhang L, Borno HT, Bucknor M, Small EJ, Aggarwal RR. PMID: 35750560.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Evaluating predictors of food insecurity among patients with cancer in the safety-net setting. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):e18550-e18550. Velazquez Manana VA, Borno BH, Trejo TE, Zhang ZS, Rodriguez Saldana RA, Leung LI, Seligman SH, Lin LT. .
      View in: Publisher Site   Mentions:
    38. Racial concordance and trust in health communications: A randomized trial of videos about prostate cancer. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):5014-5014. Loeb LS, Ravenell RJ, Gomez GS, Borno BH, Siu SK, Sanchez Nolasco ST, Byrne BN, Wilson WG, Griffith GD, Crocker CR, Sherman SR, Langford LA. .
      View in: Publisher Site   Mentions:
    39. Measuring the long commute: Experiences of a multi-ethnic cohort of patients enrolled in a financial reimbursement program for cancer clinical trials. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):e18568-e18568. Medina MS, Zhang ZS, Nieves NE, Dornsife DD, Johnson JR, Spicer SD, Borno BH. .
      View in: Publisher Site   Mentions:
    40. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    41. The Problem of Hispanic/Latinx Under-Representation in Cancer Clinical Trials. JCO Oncol Pract. 2022 05; 18(5):380-384. Espinoza-Gutarra MR, Duma N, Aristizabal P, Segarra-Vazquez B, Borno H, Halbert CH, Simon MA, Velazquez AI. PMID: 35544652.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    42. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clin Cancer Inform. 2022 05; 6:e2100182. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ. PMID: 35584338; PMCID: PMC9173564.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. MP09-16 QUALITY OF INFORMATION IN SPANISH ON BRCA AND GENETIC TESTING IN PROSTATE CANCER ON YOUTUBE. Investigative Urology. 2022 May 1; 207(Supplement 5):e142. Friedman FB, Pineault PK, Nolasco NT, Borno BH, Giri GV, Loeb LS. .
      View in: Publisher Site   Mentions:
    44. Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. JCO Oncol Pract. 2022 06; 18(6):e915-e924. Borno HT, Zhang L, Zhang S, Lin TK, Skafel A, Nieves E, Dornsife D, Johnson R, Rhoads K, Small E, Spicer D. PMID: 35196064; PMCID: PMC9191303.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    45. Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):531-531. Jindal JT, Zhang ZL, Chou CJ, Shui SD, Porten PS, Wong WA, Chan CE, Stohr SB, de Kouchkovsky dI, Borno BH, Bose BR, Kwon KD, Desai DA, Huang HF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    46. Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging. Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):109-109. Shui SD, Borno BH, Bose BR, Chou CJ, Desai DA, Fong FL, Friedlander FT, Huang HF, Koshkin KV, de Kouchkovsky dI, Hong HJ, Mohamad MO, Feng FF, Aggarwal AR, Hope HT, Small SE, Kwon KD. .
      View in: Publisher Site   Mentions:
    47. Evaluating therapeutic bladder cancer trial disparities in race/ethnicity. Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):446-446. Iyer II, Zhang ZS, Borno BH. .
      View in: Publisher Site   Mentions:
    48. Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. J Urol. 2022 03; 207(3):559-564. Loeb S, Borno HT, Gomez S, Ravenell J, Myrie A, Sanchez Nolasco T, Byrne N, Cole R, Black K, Stair S, Macaluso JN, Walter D, Siu K, Samuels C, Kazemi A, Crocker R, Sherman R, Wilson G, Griffith DM, Langford AT. PMID: 35114821.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    49. Evaluating the impact of financial toxicity among cancer clinical trial participants. International Journal of Cancer Care and Delivery. 2022 Jan 3. Borno BH, Zhang ZS, Lin LT, Zhang ZL, Palmer PN, Nguyen NC, Kaplan KC, Ryan RC. .
      View in: Publisher Site   Mentions:
    50. What do you know? The role of race/ethnicity in clinical trial knowledge among patients with a gynecologic malignancy. Gynecologic Oncology. 2022 Jan 1; 164(1):21-22. Guerra GR, Kaplan KC, Borno BH, Alvarez AE, Chapman CJ, Swanson SM, Ueda US, Chen CL. .
      View in: Publisher Site   Mentions:
    51. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. PMID: 34932386.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers. Glob Adv Health Med. 2021; 10:21649561211044693. Dragomanovich HM, Dhruva A, Ekman E, Schoenbeck KL, Kubo A, Van Blarigan EL, Borno HT, Esquivel M, Chee B, Campanella M, Philip EJ, Rettger JP, Rosenthal B, Van Loon K, Venook AP, Boscardin C, Moran P, Hecht FM, Atreya CE. PMID: 35174001; PMCID: PMC8842457.
      View in: PubMed   Mentions: 5  
    53. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139. Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. PMID: 34697300; PMCID: PMC8547221.
      View in: PubMed   Mentions: 1  
    54. The Distance Between Us: the COVID-19 Pandemic's Effects on Burnout Among Resident Physicians. Med Sci Educ. 2021 Dec; 31(6):2065-2069. Natsuhara KH, Borno HT. PMID: 34692226; PMCID: PMC8519327.
      View in: PubMed   Mentions: 6  
    55. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. PMID: 34636156; PMCID: PMC8607248.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    56. Predictors of high financial distress in a national, multiethnic sample of patients with cancer. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):149-149. Ragavan RM, Cunningham CR, Incudine IA, Borno BH, Stivers ST. .
      View in: Publisher Site   Mentions:
    57. Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):217-217. Ragavan RM, LaLanne LA, Skafel SA, Hong HJ, Odisho OA, Yousefi YS, Small SE, Borno BH. .
      View in: Publisher Site   Mentions:
    58. 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium. Annals of Oncology. 2021 Sep 21; 32:s1135. Hong HJ, Borno BH, Harismendy HO, Yousefi YS, Cinar CP, Rugo RH, Kim KM, Koshkin KV, Bailey BA, McKay MR, Small SE. .
      View in: Publisher Site   Mentions:
    59. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. J Cancer Policy. 2021 12; 30:100305. Borno HT, Lin TK, Zhang S, Skafel A, Lalanne A, Dornsife D, Johnson R, Spicer D, Small EJ, Rhoads KF. PMID: 35559801.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    60. Broad inclusion leads to maximal value – examining travel costs associated with clinical trial participation. . 2021 Aug 26. Borno BH, Zhang ZS, Nieves NE, Dornsife DD, Johnson JR, Spicer SD, Lin LT. .
      View in: Publisher Site   Mentions:
    61. Implementation of a medical oncology fellow-initiated financial toxicity screening program in outpatient medical oncology clinics. . 2021 Aug 25. Borno BH, Legaspi LN, Brondfield BS, Philip PE, Cinar CP, Zhang ZL. .
      View in: Publisher Site   Mentions:
    62. Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities. Cancer Causes Control. 2021 Oct; 32(10):1161-1172. Palmer NR, Borno HT, Gregorich SE, Livaudais-Toman J, Kaplan CP. PMID: 34189651; PMCID: PMC8416807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1092-1092. Abel AM, Melisko MM, Rugo RH, Chien CA, Diaz DI, Levine LJ, Griffin GA, McGuire MJ, Esserman EL, Borno BH, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    64. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510. Natesan ND, Zhang ZL, Oh OD, Porten PS, Meng MM, Pruthi PR, Cooperberg CM, Carroll CP, Chou CJ, Borno BH, Bose BR, Desai DA, Kwon KD, Wong WA, Feng FF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    65. Patterns in cancer management changes for patients with COVID-19 in northern California. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1535-1535. Glover GM, Wu WJ, Kwon KD, Zhang ZS, Henry HS, Wood WD, Rubin RD, Borno BH, Small SE, Schapira SL, Koshkin KV, Shah SS. .
      View in: Publisher Site   Mentions:
    66. Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):5053-5053. Aggarwal AR, Luch Sam LS, Koshkin KV, Small SE, Feng FF, de Kouchkovsky dI, Kwon KD, Friedlander FT, Borno BH, Bose BR, Chou CJ, Desai DA, Rodvelt RT, Aslam AM, Rastogi RM, Fong FL, Hope HT. .
      View in: Publisher Site   Mentions:
    67. Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e17038-e17038. Kwon KD, Paciorek PA, Zhang ZL, Borno BH, Desai DA, Bose BR, Chou CJ, Fong FL, Friedlander FT, Huang HF, Koshkin KV, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    68. Redefining Attribution From Patient to Health System-How the Notion of "Mistrust" Places Blame on Black Patients. JAMA Oncol. 2021 05 01; 7(5):780. Borno HT, Andemeskel G, Palmer NR. PMID: 33662096.
      View in: PubMed   Mentions: 7     Fields:    
    69. Assessing Clinician Attitudes and Beliefs Around Financial Toxicity Screening in Medical Oncology Clinic. . 2021 May 1; 7(4). Zhang ZS, Philip PE, Legaspi LN, Ding DL, Kuo Lin KT, Borno BH. .
      View in: Publisher Site   Mentions:
    70. Loneliness and symptom burden in oncology patients during the COVID-19 pandemic. Cancer. 2021 09 01; 127(17):3246-3253. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno HT, Chang SM, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Kober KM, Laffan A, Levine JD, Pozzar R, Rhoads K, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 33905528; PMCID: PMC9508796.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsPHPublic Health
    71. Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study. Journal of Onco-Nephrology. 2021 Apr 19; 239936932110092. Natsuhara NK, Zhang ZL, Carlos CC, Borno BH. .
      View in: Publisher Site   Mentions:
    72. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    73. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer Rep (Hoboken). 2021 08; 4(4):e1355. Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. PMID: 33621447; PMCID: PMC7995191.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    74. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):66-66. Tong TB, Borno BH, Alagala AF, Gordon GK, Small SE, Lin LA, Blanco BA, Dhawan DM. .
      View in: Publisher Site   Mentions:
    75. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):tps179-tps179. Chen CR, Karrison KT, Lawton LC, Hall HW, Borno BH, Rosu RM, Jani JA, Schuster SD, Seider SM, Efstathiou EJ, Posadas PE, Nguyen NP, Feng FF. .
      View in: Publisher Site   Mentions:
    76. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):37-37. Kwon KD, Vashisht VR, Borno BH, Aggarwal AR, Small SE, Butte BA, Huang HF. .
      View in: Publisher Site   Mentions:
    77. Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):19-19. Borno BH, Li LP, Zhang ZS, Idossa ID, Desai DA, Rodvelt RT, Bose BR, Koshkin KV, Chou CJ, Friedlander FT, Huang HF, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    78. Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):38-38. Borno BH, Zhang ZS, Gomez GS, Kaplan KC, Miaskowski MC, Hong HJ, Idossa ID, Bailey BA, Small SE. .
      View in: Publisher Site   Mentions:
    79. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2021 Feb 12; 1-16. Philip PE, Zhang ZS, Tahir TP, Kim KD, Wright WF, Bell BA, Borno BH. .
      View in: Publisher Site   Mentions:
    80. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. PMID: 33571636; PMCID: PMC7870099.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    81. Integrating Financial Toxicity Assessment in Cancer Treatment: Implications for Medical Oncology Training. Journal of Health Science Research. 2021 Jan 29; 30-38. Philip PE, Legaspi LN, Borno BH. .
      View in: Publisher Site   Mentions:
    82. Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer. Eur Urol Open Sci. 2021 Mar; 25:1-4. Loeb S, Mihalcea R, Perez-Rosas V, Xu A, Taylor J, Byrne N, Walter D, Ness M, Robbins R, Zhang S, Killeen T, Natesan D, Borno HT. PMID: 34337497; PMCID: PMC8317896.
      View in: PubMed   Mentions: 1  
    83. Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. Urol Oncol. 2021 08; 39(8):494.e7-494.e14. Borno HT, Duffy C, Zhang S, Canchola AJ, Loya Z, Golden T, Oh DL, Odisho AY, Gomez S. PMID: 33419644.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Policy and Health: Leveraging a Social Determinants of Health Framework to Alleviate the Impact of the COVID-19 Pandemic on Patients With Cancer. JCO Oncol Pract. 2021 03; 17(3):121-124. Borno HT, Idossa D, Gomez SL. PMID: 33270521.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    85. Abstract PO-276: Lazarex Cancer Foundation (LCF) financial reimbursement programs (FRP) promote equitable access and inclusion among racial/ethnic minorities in therapeutic cancer clinical trials (TCT). Cancer Epidemiology Biomarkers & Prevention. 2020 Nov 30; 29(12_Supplement):po-276-po-276. Dornsife DD, Borno BH, Spicer SD, Johnson JR. .
      View in: Publisher Site   Mentions:
    86. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. PMID: 33247633; PMCID: PMC7826487.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer. Urol Oncol. 2021 04; 39(4):233.e9-233.e14. Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR. PMID: 33158741; PMCID: PMC9208066.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    88. Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study. Journal of Clinical Oncology. 2020 Oct 10; 38(29_suppl):85-85. Borno BH, Zhang ZS, Nieves NE, Dornsife DD, Johnson JR, Spicer SD. .
      View in: Publisher Site   Mentions:
    89. Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. . 2020 Oct 5. Borno BH. .
      View in: Publisher Site   Mentions:
    90. Integrating Financial Toxicity Assessment in Cancer Treatment: Implications for Medical Oncology Training. Journal of Health Science Research. 2020 Oct 1; 5(2):30-38. Philip PE, Legaspi LN, Borno BH. .
      View in: Publisher Site   Mentions:
    91. Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center. J Nucl Med. 2021 05 10; 62(5):695-699. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. PMID: 32978283.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    92. Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic. J Pain Symptom Manage. 2020 Nov; 60(5):e25-e34. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Hammer MJ, Kenfield SA, Kober KM, Levine JD, Pozzar R, Rhoads KF, Van Blarigan EL, Van Loon K. PMID: 32889039; PMCID: PMC7462969.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansPHPublic Health
    93. Oncology patients' perceptions of and experiences with COVID-19. Support Care Cancer. 2021 Apr; 29(4):1941-1950. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 32809060; PMCID: PMC7431899.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsPHPublic Health
    94. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urol Oncol. 2020 10; 38(10):793.e1-793.e11. Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ. PMID: 32782182.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    95. COVID-19 disparities: An urgent call for race reporting and representation in clinical research. Contemp Clin Trials Commun. 2020 Sep; 19:100630. Borno HT, Zhang S, Gomez S. PMID: 32789282; PMCID: PMC7391979.
      View in: PubMed   Mentions: 27  
    96. Determining the impact of Medicaid expansion on cancer burden. Cancer. 2020 09 15; 126(18):4114-4117. Borno HT, Lin TK, Batniji RS. PMID: 32627191.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    97. The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing. JAMA Oncol. 2020 06 01; 6(6):815-816. Borno HT, Rider JR, Gunn CM. PMID: 32163096; PMCID: PMC7814415.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Abstract C053: Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Epidemiology Biomarkers & Prevention. 2020 Jun 1; 29(6_Supplement_2):c053-c053. DeRouen DM, McKinley MM, Shah SS, Borno BH, Aoki AR, Lichtensztajn LD, Leppert LJ, Brooks BJ, Chung CB, Gomez GS, Cheng CI. .
      View in: Publisher Site   Mentions:
    99. Abstract D067: The REACT study: A feasibility study to develop and test the integration of a California Cancer Registry Early Case Ascertainment process via electronic pathology reporting with an online clinical trial matching tool. Cancer Epidemiology Biomarkers & Prevention. 2020 Jun 1; 29(6_Supplement_2):d067-d067. Borno BH, Duffy DC, Zhang ZS, Golden GT, Loya LZ, Oh OD, Odisho OA, Gomez GS. .
      View in: Publisher Site   Mentions:
    100. Abstract A081: Trial Library: A pilot study to examine feasibility, acceptability, and preliminary estimates of efficacy for an online clinical trial matching website on patient-prompted conversations for prostate cancer clinical trials. Cancer Epidemiology Biomarkers & Prevention. 2020 Jun 1; 29(6_Supplement_1):a081-a081. Borno BH, Bakke BB, Prophet PA, Kim KY, Yaeger YJ, Chao CJ, Cinar CP, Kaplan KC, Small SE, Boscardin BC, Gonzales GR. .
      View in: Publisher Site   Mentions:
    101. Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes Control. 2020 Aug; 31(8):713-721. DeRouen MC, McKinley M, Shah SA, Borno HT, Aoki R, Lichtensztajn DY, Leppert JT, Brooks JD, Chung BI, Gomez SL, Cheng I. PMID: 32440828.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    102. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1590-1590. Tong TB, Borno BH, Small SE, Alagala AF, Blanco BA, Dhawan DM. .
      View in: Publisher Site   Mentions:
    103. Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17589-e17589. Borno BH, Moses MK, Monk MP, Fitch FK, Harmon HM, Flanders FS, McKay MR. .
      View in: Publisher Site   Mentions:
    104. Racial disparities and online health information: YouTube and prostate cancer clinical trials. BJU Int. 2020 07; 126(1):11-13. Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S. PMID: 32275800.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    105. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemp Clin Trials. 2020 05; 92:105997. Borno HT, Small EJ. PMID: 32272172; PMCID: PMC7194679.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    106. The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. J Oncol Pharm Pract. 2020 Jul; 26(5):1180-1189. Cheung E, Borno HT. PMID: 32122232.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    107. The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. J Racial Ethn Health Disparities. 2020 10; 7(5):996-1002. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA. PMID: 32078741; PMCID: PMC8567804.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    108. Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):502-502. Philip PE, Wright WF, Kim KD, Kwon KD, Ho HH, Ho HS, Cheung CE, Chan CE, Porten PS, Wong WA, Borno BH, Desai DA, Chou CJ, Oh OD, Aggarwal AR, Fong FL, Small SE, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    109. Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):297-297. Borno BH, Lin LT, Odisho OA, Desai DA, Koshkin KV, Werner WK, Legaspi LN, Bell BA, Hope HT. .
      View in: Publisher Site   Mentions:
    110. REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):207-207. Borno BH, Duffy DC, Zhang ZS, Loya LZ, Golden GT, Oh OD, Odisho OA, Gomez GS. .
      View in: Publisher Site   Mentions:
    111. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):187-187. Kwon KD, Wright WF, Zhang ZL, Chou CJ, Borno BH, Desai DA, Oh OD, Pollock PY, Bose BR, Huang HF, Hope HT, Friedlander FT, Fong FL, Feng FF, Small SE, Aggarwal AR, Koshkin KV. .
      View in: Publisher Site   Mentions:
    112. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. PMID: 31734020.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    113. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. PMID: 31720002; PMCID: PMC6839161.
      View in: PubMed   Mentions: 3  
    114. How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemp Clin Trials Commun. 2019 Dec; 16:100476. Borno HT, Small EJ, Zhang L, DeRouen MC, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP. PMID: 31872154; PMCID: PMC6915794.
      View in: PubMed   Mentions: 6  
    115. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020 03; 38(3):80.e1-80.e7. Kwon DH, Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. PMID: 31630993.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    116. An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study. Pilot Feasibility Stud. 2019; 5:101. Cedars B, Lisker S, Borno HT, Kamal P, Breyer B, Sarkar U. PMID: 31428442; PMCID: PMC6694525.
      View in: PubMed   Mentions: 1  
    117. Tailoring survivorship to diverse populations with genitourinary malignancies. Urol Oncol. 2020 03; 38(3):118-120. Borno HT, Dixit N. PMID: 31307880.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Food insecurity screening: A missing piece in cancer management. Cancer. 2019 Oct 15; 125(20):3494-3501. Patel KG, Borno HT, Seligman HK. PMID: 31287159.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    119. All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:302-308. Borno H, George DJ, Schnipper LE, Cavalli F, Cerny T, Gillessen S. PMID: 31099647.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    120. Germline Genetic Testing in Advanced Prostate Cancer - Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer. 2019. Channing J. Paller, Emmanuel S. Antonarakis, Tomasz M. Beer, Hala T. Borno, Maria I. Carlo, Daniel J. George, Julie N. Graff, Shilpa Gupta, Elisabeth I. Heath, Celestia S. Higano, Rana R. McKay, Alicia K. Morgans, Akash Patnaik, Daniel P. Petrylak, Matthew B. Rettig, Charles J. Ryan, Mary-Ellen Taplin, Young E. Whang, Jacob Vinson, Heather H. Cheng, Veda N. Giri. View Publication.
    121. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 08; 17(4):275-282.e1. Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN, PCCTC Germline Genetics Working Group. PMID: 31171481; PMCID: PMC6662206.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    122. An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study. Pilot and Feasibility Studies. 2019; 5:101. Benjamin Cedars, Sarah Lisker, Hala T. Borno, Puneet Kamal, Benjamin Breyer, and Urmimala Sarkar.
    123. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2019 02 01; 125(3):453-462. Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. PMID: 30444526; PMCID: PMC6340740.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    124. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019 Feb; 15(6):591-599. Borno HT, Small EJ. PMID: 30426794; PMCID: PMC6391625.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    125. Journal of Clinical Oncology. Implementation of a fellow-initiated financial toxicity screening tool in medical oncology clinics. 2018; 30_suppl(36):64-64. Samuel Craig Brondfield, Hala T. Borno, Claire Mulvey, Li-Wen Huang, Pelin Cinar. View Publication.
    126. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. PMID: 30272035; PMCID: PMC6158958.
      View in: PubMed   Mentions: 5  
    127. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. PLoS One. 2018; 13(7):e0199423. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A. PMID: 30036361; PMCID: PMC6056029.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    128. At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials. Oncologist. 2018 10; 23(10):1242-1249. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. PMID: 29700209; PMCID: PMC6263122.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    129. Journal of Clinical Oncology. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. 2018; 36(6_suppl ):267-267. Hala T Borno, Joseph P. McGuire, Ann C. Griffin, Charles J. Ryan, Celia Kaplan, Eric Jay Small. View Publication.
    130. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):267-267. Borno BH, McGuire MJ, Griffin GA, Ryan RC, Kaplan KC, Small SE. .
      View in: Publisher Site   Mentions:
    131. CaPSURE update: Examining primary treatment and survival among men with prostate cancer and bony metastatic disease. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):275-275. Borno BH, Cowan CJ, Zhao ZS, Carroll CP, Ryan RC. .
      View in: Publisher Site   Mentions:
    132. Blood and conflict: managing bleeding disorders in Gaza. East Mediterr Health J. 2018 Jan 02; 23(11):786-787. Borno H. PMID: 29319151.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. JRSM Open. 2017 Jun; 8(6):2054270417698632. Natalini J, Borno H, Jin L, Jensen T. PMID: 28620506; PMCID: PMC5464381.
      View in: PubMed   Mentions: 1  
    134. Improving documentation of surrogate decision makers in medical oncology clinic. Journal of Clinical Oncology. 2017 Mar 10; 35(8_suppl):63-63. Wong WM, Borno BH, Mahajan MR, Bischoff BK, Calton CB, Bergsland BE, Kim KW, Aggarwal AR, Tsai TK, Cinar CP. .
      View in: Publisher Site   Mentions:
    135. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016 07; 21(3):145-6. Borno H, Siegel A, Ryan C. PMID: 26888478.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    136. Incidence of cleft lip and palate in the palestinian territories: a retrospective study from the Makassed Hospital neonatal unit. Cleft Palate Craniofac J. 2014 Jul; 51(4):472-5. Borno HT, Hussein EA, Dudin A, van Aalst JA. PMID: 23551076.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    137. Cleft Lip and Palate Diagnosis and Management. Birthing and Building Nascent Cleft Teams in Developing Countries. 2012; 871-877. Hussein E, Borno HT, van Aalst JA.
    Hala's Networks
    Concepts (204)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (101)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.